High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne Vulgaris
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Isotretinoin is the most effective treatment for acne. The ideal dosing regimen is unknown. OBJECTIVE: To determine the rates of relapse of acne vulgaris and retrial of isotretinoin after high cumulative-dose treatment and the changes to the adverse effect profile. DESIGN, SETTING, AND PARTICIPANTS: A prospective, observational, intervention study was conducted from August 1, 2008, to August 31, 2010, in a single academic tertiary care center with multiple providers. A total of 180 patients with acne resistant to other treatments were enrolled. Of these, 116 participated in the 12-month follow-up survey, for a response rate of 64.4%. EXPOSURE: Patients received isotretinoin, with dosing based on the providers' judgment. Patients were divided into 2 groups on the basis of cumulative dosing (<220 mg/kg and ≥ 220 mg/kg). MAIN OUTCOMES AND MEASURES: Relapse (treatment with a prescription topical or oral acne medication after a course of isotretinoin) or retrial (retreatment with isotretinoin) at 12-month follow-up and adverse effects experienced during and after 12 months of treatment. RESULTS The mean age of the participants was 19.3 years, 51.9% were female, and 74.1% were white. At 12 months' follow-up, 97.4% of the patients reported that their acne was improved. Overall, acne in 32.7% of patients in the study relapsed at 12 months, and 1.72% of the patients required a retrial. In the lower-dose treatment group (<220 mg/kg), the relapse rate was 47.4% (95% CI, 32.3%-63.0%) compared with 26.9% (95% CI, 18.3%-37.8%) in the high-dose group (P = .03). Almost 100% of the patients in both treatment groups developed cheilitis and xerosis during treatment. Retinoid dermatitis was significantly more common in the high-dose treatment group (53.8% vs 31.6%; P = .02). None of the other adverse effects was significantly different between the 2 groups. CONCLUSIONS AND RELEVANCE: The dosing regimen used in the present study is considerably higher than that used in previous studies of isotretinoin. At 1 year after completion of isotretinoin treatment, we found that patients receiving 220 mg/kg or more had a significantly decreased risk of relapse. Rash was the only adverse effect that was significantly more common in the high-dose group during treatment. This study suggests that significantly higher doses of isotretinoin are effective for treating acne and decreasing relapse rates without increasing adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isotretinoin therapy for acne: results of a multicenter dose-response study
Strauss, J. S., Rapini, R. P., Shalita, A. R., Konecky, E., Pochi, P. E., Comite, H., & Exner, J. H. (1984) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(84)80100-0 · Cited by 223
Low-dose isotretinoin in the treatment of acne vulgaris
Amichai, B., Shemer, A., & Grunwald, M. H. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.11.1061 · Cited by 177
Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review
Marqueling, A. L., & Zane, L. T. (2005) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2005.04.003 · Cited by 166
Isotretinoin use and the risk of inflammatory bowel disease: a case-control study
Crockett, S. D., Porter, C. Q., Martin, C. F., Sandler, R. S., & Kappelman, M. D. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.124 · Cited by 161
Lee, J. W., Yoo, K. H., Park, K. Y., Han, T. Y., Li, K., Seo, S. J., & Hong, C. K. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10152.x · Cited by 127
Bernstein, C. N., Nugent, Z., Longobardi, T., & Blanchard, J. F. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.417 · Cited by 118
Cited by
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
Management of Acne Vulgaris: A Review
Eichenfield, D. Z., Sprague, J., & Eichenfield, L. F. (2021) · JAMA · doi:10.1001/jama.2021.17633 · Cited by 389
Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris
O’Neill, A. M., & Gallo, R. L. (2018) · Microbiome · doi:10.1186/s40168-018-0558-5 · Cited by 334
Khalil, S., Bardawil, T., Stephan, C., Darwiche, N., Abbas, O., Kibbi, A. G., Nemer, G., & Kurban, M. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1309349 · Cited by 217
“This study, however, has multiple limitations and further studies are needed to confirm these results (41).”
BackgroundResultRole of sebaceous glands in inflammatory dermatoses
Shi, V. Y., Leo, M., Hassoun, L., Chahal, D. S., Maibach, H. I., & Sivamani, R. K. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.015 · Cited by 161
Metadata
- Authors
- Blasiak, R. C., Stamey, C. R., Burkhart, C. N., Lugo-Somolinos, A., & Morrell, D. S.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-12-01
- Volume
- 149
- Issue
- 12
- Pages
- 1392
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2116713827
- Cited by
- 138
- References
- 6
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.